State drugs authority recommends anti-COVID drug from Regeneron

The Czech State Drugs Control Institute (SUKL) recommended an anti-coronavirus drug by the Regeneron company to be used in Czechia even though it has not been registered yet, SUKL director Irena Storova tweeted today. The drug is based on a combination of two monoclonal antibodies, Casirivimab and Imdevimab. It is meant for high-risk outpatients. A week ago, the SUKL recommended the first monoclonal-based drug from the U.S. Eli Lilly firm and its usage was approved by the Health Ministry, too, some days after.